Treatment of recurrent disease in lung cancer

Seminars in Surgical Oncology

Volumn 21, Issue 2, 2003, Pages 122-127

  Zimmermann, Frank B ^a   Molls, Michael ^a   Jeremic, Branislav ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

Cancer recurrence; Chemotherapy; Lung cancer; Radiotherapy; Surgery

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE; DNA TOPOISOMERASE INHIBITOR; DOCETAXEL; DOXORUBICIN; GEFITINIB; GEMCITABINE; IFOSFAMIDE; IRINOTECAN; NAVELBINE; PACLITAXEL; TAXANE DERIVATIVE; TOPOTECAN; VINCRISTINE;

BRACHYTHERAPY; CANCER CHEMOTHERAPY; CANCER PALLIATIVE THERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURGERY; CLINICAL TRIAL; HUMAN; LUNG CANCER; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; METASTASIS; PRIORITY JOURNAL; QUALITY OF LIFE; RADIATION DOSE; RADIATION PNEUMONIA; RECURRENT CANCER; REOPERATION; REVIEW; SURVIVAL TIME;

CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SMALL CELL; COMBINED MODALITY THERAPY; HUMANS; LUNG NEOPLASMS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PROGNOSIS; SURVIVAL ANALYSIS;

EID: 0141927962     PISSN: 87560437     EISSN: None     Source Type: Journal    
DOI: 10.1002/ssu.10029     Document Type: Review

References (68)

1. Martini N, Melamed MR: Multiple primary lung cancers. J Thorac Cardiovasc Surg 1975;70:606-612.
2. Matthews MJ, Kanhouwa S, Pickrer J, Robinette D: Frequency of residual and metastatic tumor in patients undergoing curative surgical resection for lung cancer. Cancer Chemother Rep 1973;4:63-66.
3. Mountain CR, Hermes KE: Management implications of surgical staging studies. In Muggia F, Rosenzweig M (eds). "Lung cancer: progress in therapeutic research." New York: Raven; 1979; p. 233.
4. Pairolero PC, Williams DE, Bergstralh EJ, et al: Postsurgical stage I bronchogenic carcinoma: morbid implications of recurrent disease. Ann Thorac Surg 1984;38:331-336.
5. Al-Kattan K, Sepsas E, Fountain SW, Townsend ER: Disease recurrence after resection for stage I lung cancer. Eur J Cardiothorac Surg 1997;12:380-384.
6. Virgo KS, McKirgan LW, Caputo MCA, et al: Post-treatment management options for patients with lung cancer. Ann Surg 1995;222:700-710.
7. Walsh GL, O'Connor M, Willis KM, et al: Is follow-up of lung cancer patients after resection medically indicated and cost-effective? Ann Thorac Surg 1995;60:1563-1572.
8. Martini N, Bains MS, Burt ME, et al: Incidence of local recurrence and second primary tumor in resected stage I lung cancer. J Thorac Cardiovasc Surg 1995;109:120-129.
9. Voltolini L, Paladini P, Luzzi L, et al: Iterative surgical resections for local recurrent and second primary bronchogenic carcinoma. Eur J Cardiothorac Surg 2000;18:529-534.
10. Younes RN, Gross JL, Deheinzelin D: Follow-up in lung cancer. How often and for what purpose? Chest 1999;115:1494-1499.
11. Westeel V, Choma D, Clement F, et al: Relevance of an intensive postoperative follow-up after surgery for non-small cell lung cancer. Ann Thorac Surg 2000;70:1185-1190.
12. Watanabe Y, Shimizu J, Oda M, et al: Second surgical intervention for recurrent and second primary bronchogenic carcinoma. Scand J Thorac Cardiovasc Surg 1992;26:73-78.
13. Gabler A, Liebig S: Reoperation for bronchial carcinoma. Thorax 1980;35:668-680.
14. Dartevelle P, Khalif J: Surgical approach to local recurrence and the second primary lesion. In Delarue NC, Eschapasse H (eds). "International trend in general thoracic surgery." Vol. 1. Philadelphia, PA: WB Saunders; 1985; p. 156-163.
15. Lesser T, Brenner A, Bartel M: Das rezidiv beim kurativ operierten nicht-kleinzelligen bronchialkarzinom. Zentralbl Chir 1997;122:642-648.
16. Becker HP, Radomsky J, Hartel W: Das rezidiv des nichtkleinzelligen bronchialkarzinoms:indikation und ergebnisse der chirirgischen behandlung. Pneumologie 1990;44:1106-1109.
17. Regnard JF, Icard P, Magdeleinat P, et al: Completion pneumonectomy: experience in eighty patients. J Thorac Cardiovasc Surg 1999;117:1095-1101.
18. Lamont JP, Kakuda JT, Smith D, et al: Systematic postoperative radiologic follow-up in patients with non-small cell lung cacner for detecting second primary lung cancer in stage I A. Arch Surg 2002;137:935-938.
19. Sawyer TE, Bonner JA, Gould PM, et al: Predictors of subclinical nodal involvement in clinical stages I and II non-small cell lung cancer. Implications in the inoperable and three-dimensional dose-escalation settings. Int J Radiat Oncol Biol Phys 1999;43:965-970.
20. Green N, Kern W: The clinical course and treatment results of patients with postresection locally recurrent lung cancer. Cancer 1978;42:2478-2485.
21. Yano T, Hara N, Ichinose Y, et al: Local recurrence after complete resection for non-small-cell carcinoma of the lung. Significance of local control by radiation treatment. J Thorac Cardiovasc Surg 1994;107:8-12.
22. Kopelson G, Choi NCH: Radiation therapy for postoperative local-regionally recurrent lung cancer. Int J Radiat Oncol Biol Phys 1980;6:1503-1506.
23. Shaw EG, Brindle JS, Creagan ET, et al: Locally recurrent non-small-cell lung cancer after complete surgical resection. Mayo Clin Proc 1992;67:1129-1133.
24. Curran WJ Jr, Herbert SH, Stafford PM, et al: Should patients with post-resection locoregional recurrence of lung cancer receive aggressive therapy? Int J Radiat Oncol Biol Phys 1992;24:25-30.
25. Leung J, Ball D, Worotniuk T, Laidlaw C: Survival following radiotherapy for post-surgical locoregional recurrence of non-small cell lung cancer. Lung Cancer 1995;13:121-127.
26. Emami B, Graham MV, Deedy M, et al: Radiation therapy for intrathoracic recurrence of non-small cell lung cancer. Am J Clin Oncol 1997;20:46-50.
27. Kagami Y, Nishio M, Narimatsu N, et al: Radiotherapy for locoregional recurrent tumors after resection of non-small cell lung cancer. Lung Cancer 1998;20:31-35.
28. Jeremic B, Shibamoto Y, Milicic B, et al: External beam radiation therapy alone for loco-regional recurrence of non-small-cell lung cancer after complete resection. Lung Cancer 1999;23:135-142.
29. Law MR, Henk JM, Lennox SC, Hodson ME: Value of radiotherapy for tumor on the bronchial stump after resection of bronchial carcinoma. Thorax 1982;37:496-499.
30. Kono K, Murakami M, Sasaki R, et al: Radiation therapy for non-small cell lung cancer with postoperative intrathoracic recurrence. Nippon Igaku Hoshasen Gakkai Zasshi 1998;58:18-24.
31. Jeremic B, Bamberg M: External beam radiation therapy for bronchial stump recurrence of non-small-cell lung cancer after complete resection. Radiother Oncol 2002;64:251-257.
32. Green N, Melbye RW: Lung cancer: retreatment of local recurrence after definitive irradiation. Cancer 1982;49:865-868.
33. Jackson MA, Ball DL: Palliative retreatment of locally recurrent lung cancer after radical radiotherapy. Med J Aust 1987;147:391-394.
34. Montebello JF, Aron BS, Manatunga AK, et al: The reirradiation of recurrent bronchogenic carcinoma with external beam irradiation. Am J Clin Oncol 1993;16:482-488.
35. Gressen EL, Werne-Wasik M, Cohn J, et al: Thoracic reirradiation for symptomatic relief after prior radiotherapeutic management for lung cancer. Am J Clin Oncol 2000;23;160-163.
36. Okamoto Y, Murakami M, Yoden E, et al: Reirradiation for locally recurrent lung cancer previously treated with radiation therapy. Int J Radiat Oncol Biol Phys 2002;52:390-396.
37. Mendiondo OA, Dillon M, Beach LJ: Endobronchial brachytherapy in the treatment of recurrent bronchogenic carcinoma. Int J Radiat Oncol Biol Phys 1983;9:579-582.
38. Seagren SL, Harrell JH, Horn RA: High dose rate intraluminal irradiation in recurrent endobronchial carcinoma. Chest 1985;88:810-814.
39. Mehta MP, Shahabi S, Jarjour NN, Kinsella TJ: Endobronchial irradiation for malignant airway obstruction. Int J Radiat Oncol Biol Phys 1989;17:847-851.
40. Bedwinek J, Petty A, Bruton C, et al: The use of high dose rate endobronchial brachytherapy to palliate symptomatic endobronchial recurrence of previously irradiated bronchogenic carcinoma. Int J Radiat Oncol Biol Phys 1991;22:23-30.
41. Sutedja G, Baris G, Schaake-Koning C, van Zandwijk N: High dose rate brachytherapy in patients with local recurrences after radiotherapy of non-small cell lung cancer. Int J Radiat Oncol Biol Phys 1992;24:551-553.
42. Gauwitz M, Ellerbroek N, Komaki R, et al: High dose endobronchial irradiation in recurrent bronchogenic carcinoma. Int J Radiat Oncol Biol Phys 1992;23:397-400.
43. Gustafson G, Vicini F, Freedman L, et al: High dose rate endobronchial brachytherapy in the management of primary and recurrent bronchogenic malignancies. Cancer 1995;75:2345-2350.
44. Delclos ME, Komaki R, Morice RC, et al: Endobronchial brachytherapy with high-dose-rate remote afterloading for recurrent endobronchial lesions. Radiology 1996;201:279-282.
45. Kelly JF, Delclos ME, Morice RC, et al: High-dose-rate endobronchial brachytherapy effectively palliates symptoms due to airway tumors: the 10-year M.D.Anderson Cancer Center experience. Int J Radiat Oncol Biol Phys 2000;48:697-702.
46. Massarelli E, Andre F, Liu DD, et al: A retrospective analysis of the outcome of patients who have been received two prior chemotherapy regimens including platinum and docetaxel for recurrent non-small cell lung cancer. Lung Cancer 2003;39:55-61.
47. Shepherd FA, Dancey J, Ramlau R, et al: Prospective randomized trial of docetaxel vs best supportive care in patients with non small cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol 2000;18:2095-2103.
48. Fossella FV, DeVore R, Kerr RN, et al: Randomized phase III trial of docetaxel vs vinorelbine or ifosfamide in patients with advanced non-small cell lung cancer previously treated with platinum-containing chemotherapy regimens: the TAX 320 non-small cell lung cancer study group. J Clin Oncol 2000;18:2354-2360.
49. Dancey J, Shepherd FA, Ramlau R, et al: Quality of life (QOL) assessment in randomized study of taxotere (TAX) versus best supportive care (BSC) in non-small cell lung cancer (NSCLC) patients previously treated with platinum-based chemotherapy [Abstract]. Proc Am Soc Clin Oncol 1999;18:491a.
50. Herbst RS: Dose-comparative monotherapy trials of ZD 1839 in previously treated non-small cell lung cancer patients. Semin Oncol 2003;30:30-38.
51. Huisman C, Smit EF, Giaccone G, Postmus PE: Second-line chemotherapy in relapsing or refractory non-small cell lung cancer: a review. J Clin Oncol 2000;18:3722-3730.
52. Belani CP: Single agents in the second-line treatment of non-small cell lung cancer. Semin Oncol 1998;25:10-14.
53. Muller H, Guadagni S: Regional plus systemic chemotherapy: an effective treatment in recurrent non-small cell lung cancer. Eur J Surg Oncol 2001;27:190-195.
54. Giaccone G, Donadio M, Bonardi G, et al: Teniposide in the treatment of small-cell lung cancer: the influence of prior chemotherapy. J Clin Oncol 1988;6:1264-1270.
55. Smit EF, Fokkema E, Biesma B, et al: A phase II study of paclitaxel in heavily pretreated patients with small-cell lung cancer. Br J Cancer 1998;77:347-351.
56. Van der Lee I, Postmus P, Smit E, et al: The activity of Gemcitabine in patients with resistant small cell lung cancer (SCLC): a phase II study [Abstract]. Proc Am Soc Clin Oncol 1999;18:467.
57. Furuse K, Kubota K, Kawahara M, et al: Phase II study of vinorelbine in heavily previously treated small cell lung cancer. Oncology 1996;53:169-172.
58. von Pawel J, Schiller JH, Shepherd FA, et al: Topotecan vs cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent small-cell lung cancer. J Clin Oncol 1999;17:658-667.
59. von Pawel J, Gatzemeier U, Pujol JL, et al: Phase II comparator study of oral versus intravenous topotecan in patients with chemosensitive small-cell lung cancer. J Clin Oncol 2001;19:17431-749.
60. Masuda N, Matsui K, Negoro S, et al: Combination of irinotecan and etoposide for treatment of refractory or relapsed small-cell lung cancer. J Clin Oncol 1998;16:3329-3334.
61. Ardizzoni A, Manegold C, Debruyne C, et al: Combination chemotherapy with cisplatin and topotecan as second-line treatment of sensitive and refractory small cell lung cancer (SCLC):an EORTC LCCG phase II study. Clin Cancer Res 2003;9:143-150.
62. Lusch G, Rausch G, Kosierowski R: Phase II study of daily oral etoposide and hexamethylmelamine (altretamine) in relapsed small cell lung cancer (SCLC) [Abstract]. Proc Am Soc Clin Oncol 1999;18:478a.
63. Rushing DA, Tipping SJ, Close LH, et al: Phase I study of combination of irinotecan (CPT-11) and paclitaxel (Taxol) in previously treated patients with small cell lung cancer 9SCLC) [Abstract]. Proc Am Soc Clin Oncol 1999;18;484a.
64. Agelaki S, Agelidou A, Blazogiannakis G, et al: A phase II study of paclitaxel (P) and carboplatin (C) as second-line treatment in patients with small cell lung cancer [Abstract]. Eur J Cancer 1999;35:S258.
65. Kosmas C, Tsavaris NB, Malamos NA, et al: Phase II study of paclitaxel, ifosfamid, and cisplatin as second-line treatment in relapsed small-cell lung cancer. J Clin Oncol 2001;19:119-126.
66. Fidias P, Lynch TJ Jr: Targeted therapy of SCLC using N901-blocked ricin. Clin Lung Cancer 2002;3:219-222.
67. Fossella FV, Tolcher A, Elliott M: Phase I trial of the monoclonal antibody conjugate, BB-10901, for relapsed (refractory small cell lung cancer (SCLC) and other neuroendocrine (NE) tumors [Abstract]. Proc Am Soc Clin Oncol 2002;21:309.
68. Ciardiello F, Tortora G: A novel approach in the treatment of cancer: targeting the epidermal growth factor receptor. Clin Cancer Res 7:2958-2970, 2001.